Please ensure Javascript is enabled for purposes of website accessibility

Bouncing Biotech? Here Are 3 Stocks to Buy

By Todd Campbell - Feb 17, 2016 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Gilead Sciences, Celgene Corp., and Regeneron have needle-moving plans in the works that could reward long-term investors.

Image source: Flickr user stockmonkeys.com.

The NASDAQ Biotechnology ETF (IBB -1.25%) has fallen 23.5% this year, but its 4.27% gain since Feb. 8 is double the return of the S&P 500, and if that bounce continues, then investors might want to consider picking up shares in Gilead Sciences (GILD -1.42%), Celgene Corp. (CELG), and Regeneron Pharmaceuticals (REGN -1.88%). Returns for all three of these companies are outpacing the industry recently and each has important catalysts coming that could drive sales and profit significantly higher.

No. 1: Dominating markets
Worry that Merck & Co.'s (MRK 0.31%) newly approved HCV drug Zepatier will push Gilead Sciences off the podium in hepatitis C could be overblown, and if they are, then shares in the company could be too cheap.

Zepatier is challenging Gilead Sciences Harvoni, the $14 billion per year blockbuster drug most prescribed to hepatitis C patients, but even though Zepatier launched with a lower price, Gilead Sciences may remain the dominant player.

Zepatier is only approved to treat genotype 1 and genotype 4 patients and patients must be tested to see if they have specific polymorphisms of the disease that reduce Zepatier's efficacy. Zepatier is also contraindicated in people with moderate to severe liver disease and the shortest duration of treatment with it lasts 12 weeks.

That may not match up competitively to Harvoni, which can be used to treat patients with genotypes 1, 4, 5, and 6. Harvoni doesn't require testing for polymorphisms, it isn't contraindicated in moderate to severe liver disease, and up to 45% of genotype 1 patients qualify for an industry leading 8-week short-duration regimen.

Harvoni's advantages and the potential Food and Drug Administration approval of the company's next-generation HCV drug this summer have me thinking investors are right to warm up to Gilead Sciences' shares, especially since they're still trading at a bargain-bin 7.3 times forward EPS valuation.

Image source: Celgene Corp.

No. 2: Advancing its pipeline
With more than $9 billion in sales last year, Celgene Corporation has plenty of financial firepower to invest in new therapies that could help it deliver on its $21 billion sales goal in 2020.

Sales of the company's top-selling Revlimid grew to $5.8 billion in 2015 and that cash -- along with cash tied to growing sales for its cancer drug Abraxane, multiple myeloma therapy Pomalyst, and psoriasis drug Otezla -- allowed Celgene to plow $2 billion into R&D last year, which was roughly $400 million more than the company spent on R&D in 2014.

R&D investments have it on pace to report data from least 18 phase 3 studies between mid-2016 and mid-2018.

A lot of those studies are for drugs it already has on the market and that means that if the data is solid, then label expansions could quickly contribute to Celgene's top and bottom lines. 

Results are also on tap for entirely new compounds, including the the oral MS drug, ozanimod, and the Crohn's disease drug, GED-0301. Ozanimod MS data should be available in 2017 and results from GED-0301's study should be ready in 2018.

Because Celgene's 2020 revenue target translates into a forecast for at least $13 in EPS that year and actual results could end up being higher because of its R&D efforts, now could be the perfect time to buy.

No. 3: Multiple blockbuster opportunities
Rapid sales growth for the company's vision loss drug Eylea have led to Regeneron Pharmaceuticals' shares returning an eye-opening 331% since 2012, but the future could be just as bright because of its recently launched cholesterol-lowering drug Praluent and promising drugs addressing various multibillion-dollar indications that are in the works.

Eylea is used to treat age-related macular degeneration and diabetic macular edema and because the patient population for each of those indication is growing, demand for the drug pushed its sales up more than 40% to $4.1 billion in 2015.

Praluent may not end up being as big of a seller as Eylea, but tens of millions of patients with high cholesterol could eventually benefit from using it alongside statins. Given that insurance reimbursement is getting easier and cardiovascular outcomes study results are on the horizon, Praluent's potential revenue opportunity remains massive.

Image source: Regeneron Pharmaceuticals.

Another similar needle-moving opportunity could be coming in October, when the FDA is set to make a decision on the company's rheumatoid arthritis drug sarilumab. Sarilumab has a good shot at carving away hundreds of millions of dollars in sales from existing RA therapies, including Humira -- the planet's best-selling drug -- and if results from a study comparing sarilumab against Humira are positive, then sarilumab could become a blockbuster drug someday, too.

Additionally, Regeneron's dupilumab is in phase 3 studies as a treatment for eczema, a condition affecting 3 million Americans, and asthma, another major market indication that affects millions of people. If those studies succeed, then a dupilumab approval could conceivably mean that Regeneron Pharmaceuticals has four different billion-dollar blockbusters on the market in the next few years.

Admittedly, Regeneron Pharmaceuticals' shares aren't as cheap as those of Gilead Sciences and Celgene, but it may offer the biggest opportunity for profit growth of the three over the next decade, and for that reason, it could be worth owning. 

 

Todd Campbell owns shares of Celgene and Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$91.32 (0.31%) $0.28
Celgene Corporation Stock Quote
Celgene Corporation
CELG
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$624.38 (-1.88%) $-11.96
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$65.08 (-1.42%) $0.94
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$128.77 (-1.25%) $-1.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.